Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says
This article was originally published in The Tan Sheet
Executive Summary
Use of a "black box" warning on OTC acetaminophen labeling would be an inappropriate means for alerting consumers about potential liver damage, two consultants to FDA's Nonprescription Drugs Advisory Committee said Sept. 19
You may also be interested in...
McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol
McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.
Sen. Grassley Questions FDA’s Response To Acetaminophen Concerns
Sen. Chuck Grassley, R-Iowa, asks FDA to account for its lag time in reacting to acetaminophen safety concerns in a March 20 letter to Commissioner Andrew von Eschenbach
Tylenol Ads Touting Superior Safety To NSAIDs May Mislead Consumers – NAD
Ads for Tylenol Arthritis Pain claiming the analgesic has fewer drug interactions than Advil and Aleve could be misinterpreted by consumers and should be modified or discontinued, the National Advertising Division concludes in an upcoming Case Reports